We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-20.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.95B
AUM Growth
-$629M
Cap. Flow
+$37M
Cap. Flow %
1.9%
Top 10 Hldgs %
47.94%
Holding
79
New
8
Increased
5
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$67.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$57.6M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$49.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$36.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$26.1M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$139M
2
ITOS
iTeos Therapeutics
ITOS
+$41.9M
3
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$4.88M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$4.88M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.15%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
51
Oric Pharmaceuticals
ORIC
$1.08B
$5.63M 0.29%
1,054,000
+854,000
+427% +$7.69M
BDTX icon
52
Black Diamond Therapeutics
BDTX
$104M
$5.58M 0.29%
2,014,858
– –
ODT
53
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$5.55M 0.29%
4,207,086
– –
CDAK
54
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$5.33M 0.27%
850,065
– –
BMEA icon
55
Biomea Fusion
BMEA
$94.7M
$5.3M 0.27%
1,188,405
– –
BLSA
56
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.93M 0.25%
500,000
– –
PANA
57
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.25%
500,000
– –
EPIX
58
DELISTED
ESSA Pharma
EPIX
$4.49M 0.23%
724,500
– –
EQRX
59
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.13M 0.21%
1,000,000
– –
RNAC icon
60
Cartesian Therapeutics
RNAC
$240M
$4.04M 0.21%
109,469
– –
OBIO icon
61
Orchestra BioMed
OBIO
$222M
$3.96M 0.2%
400,000
– –
BCAB icon
62
BioAtla
BCAB
$6.14M
$3.45M 0.18%
13,727
– –
DBVT
63
DBV Technologies
DBVT
$862M
$3.39M 0.17%
213,460
– –
ALGS icon
64
Aligos Therapeutics
ALGS
$32.7M
$3.28M 0.17%
61,042
– –
ELEV
65
DELISTED
Elevation Oncology
ELEV
$2.2M 0.11%
872,780
– –
OMEG
66
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.96M 0.1%
200,000
– –
IRON icon
67
Disc Medicine
IRON
$2.84B
$1.81M 0.09%
43,333
– –
LITS
68
Lite Strategy Inc
LITS
$35M
$1.75M 0.09%
145,655
– –
GNCA
69
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.42M 0.07%
1,134,453
– –
CABA icon
70
Cabaletta Bio
CABA
$448M
$1.1M 0.06%
540,000
– –
TARA icon
71
Protara Therapeutics
TARA
$229M
$1.07M 0.05%
209,227
– –
NUVB.WS
72
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$203K 0.01%
266,666
– –
BLCM
73
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$123K 0.01%
+56,950
New +$92.6K
SRZNW icon
74
Surrozen Inc Warrant
SRZNW
$17K ﹤0.01%
+66,666
New +$33.6K
MLTX icon
75
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-400,000
Closed -$3.96M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Boxer Capital held 79 positions worth $1.95B, down 24% from $2.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital's Q1 2022 filing shows 8 new, 5 increased, 2 reduced and 5 closed positions. Its largest new stake was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $139M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 87% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q1 2022 buy was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M.
  • Boxer Capital added most to Acadia Pharmaceuticals in Q1 2022, an estimated $26.1M increase.
  • Boxer Capital's biggest Q1 2022 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $139M.
  • Boxer Capital fully exited Jiya Acquisition Corp. Class A Common Stock in Q1 2022, selling an estimated $4.88M.
  • Boxer Capital's ten largest holdings make up 48% of its $1.95B portfolio in Q1 2022.
  • Boxer Capital opened 8 new positions and closed 5 in Q1 2022.
  • Boxer Capital's portfolio value fell 24% quarter-over-quarter to $1.95B.

Based on Boxer Capital's 13F filing for Q1 2022, filed 16 May 2022.